French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Sanofi will acquire Vicebio for USD 1.15 bn, gaining RSV/hMPV vaccine candidates plus the Molecular Clamp platform for refrigeration‑stable combination vaccines. Deal expected by Q4 2025, supporting ...

Sanofi (NASDAQ:SNY)’s vaccine is supplied as a ready-to-use liquid in single-dose vials, streamlining administration. This expansion comes amid a recent rise in U.S. meningococcal disease cases ...

TORONTO, May 30, 2024 /CNW/ - Today, Sanofi, a global healthcare company, announced the opening of a new state-of-the-art pediatric and adult vaccine manufacturing facility at its Toronto Campus ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read more here.

French pharmaceutical and healthcare company Sanofi officially handed over a cooperation document for vaccine production technology transfer to leaders of the VNVC Vaccine and Biological Products ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D for the British pharma. | After nearly 25 years with Sanofi ...